[Form 4] Oncology Institute, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Oncology Institute, Inc. (TOI)11/18/2025, the reporting person acquired 141,149 shares of common stock in a transaction coded "J". After this transaction, the director beneficially owned 250,206 shares, held directly.

According to the explanation, these shares were received through an in-kind distribution from M33 Growth I, L.P. to its limited partners on a pro rata basis, in accordance with their pecuniary interests, relying on Rules 16a-9 and 16a-13 under the Securities Exchange Act of 1934.

11/20/2025 - 04:02 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ling Gabriel

(Last) (First) (Middle)

18000 STUDEBAKER ROAD, SUITE 800

(Street)

CERRITOS CA 90703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/18/2025		J(1)		141,149	A	(1)	250,206	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of shares of common stock of the Issuer received by the reporting person through an in-kind distribution by M33 Growth I, L.P. to its limited partners and on a pro rata basis in accordance with their pecuniary interests therein in reliance on Rules 16a-9 and 16a-13 under the Securities Exchange Act of 1934, as amended.

	/s/ Gabriel Ling	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Oncology Institute (TOI) report on this Form 4?

The filing reports that a director of Oncology Institute, Inc. (TOI) acquired 141,149 shares of common stock on 11/18/2025 in a transaction coded "J".

How many Oncology Institute (TOI) shares does the reporting person own after this transaction?

Following the reported transaction, the director beneficially owned 250,206 shares of Oncology Institute common stock, held directly.

What is the relationship of the reporting person to Oncology Institute (TOI)?

The reporting person is identified as a Director of Oncology Institute, Inc. (TOI).

What is the nature of the 141,149 TOI shares acquired in this Form 4?

The 141,149 shares of TOI common stock were received via an in-kind distribution from M33 Growth I, L.P. to its limited partners on a pro rata basis.

Which SEC rules are referenced for the Oncology Institute (TOI) in-kind distribution?

The in-kind distribution relies on Rules 16a-9 and 16a-13 under the Securities Exchange Act of 1934, as stated in the explanation of responses.

Is this Oncology Institute (TOI) Form 4 filed by one or multiple reporting persons?

The Form 4 is indicated as being filed by one reporting person, not by a group.